<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2906222286
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Bivoneb
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NEBIVOLOL HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        51.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C07AB12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Bivoneb contains Nebivolol, a cardiovascular drug belonging to the group of selective beta- blocking agents (i.e. with a selective action on the cardiovascular system). It prevents increased heart rate, controls heart pumping strength. It also exerts a dilating action on blood vessels, which contributes as well to lower blood pressure.</p><p>It is used to treat raised blood pressure (hypertension).</p><p>Bivoneb is also used to treat mild and moderate chronic heart failure in patients aged 70 or over, in addition to other therapies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Bivoneb</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to Nebivolol or any of the other ingredients of this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have one or more of the following disorders:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious circulation problems in the arms or legs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very slow heartbeat (less than 60 beats per minute)</p><p>&nbsp;</p><p>Certain other serious heart rhythm problems (e.g. 2nd and 3rd degree atrioventricular block, heart conduction disorders).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure, which has just occurred or which has recently become worse, or you are receiving treatment for circulatory shock due to acute heart failure by intravenous drip feed to help your heart work</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma or wheezing (now or in the past)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; untreated phaeochromocytoma, a tumour located on top of the kidneys (in the adrenal glands)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver function disorder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a metabolic disorder (metabolic acidosis), for example, diabetic ketoacidosis.</p><p>&nbsp;</p><p>Warnings and Precautions</p><p>Talk to your doctor or pharmacist before taking Bivoneb.</p><p>Inform your doctor if you have or develop one of the following problems:</p><p>-&nbsp; abnormally slow heartbeat</p><p>-&nbsp; a type of chest pain due to spontaneously occurring heart cramp called Prinzmetal angina</p><p>-&nbsp; untreated chronic heart failure</p><p>-&nbsp; 1st degree heart block (a kind of light heart conduction disorder that affects heart rhythm)</p><p>-&nbsp; poor circulation in the arms or legs, e.g. Raynaud&rsquo;s disease or syndrome, cramp-like pains when walking</p><p>-&nbsp; prolonged breathing problems</p><p>-&nbsp; diabetes: This medicine has no effect on blood sugar, but it could conceal the warning signs of a low sugar level (e.g. palpitations, fast heartbeat).</p><p>-&nbsp; Overactive thyroid gland: This medicine may mask the signs of an abnormally fast heart rate due to this condition</p><p>-&nbsp; allergy: This medicine may intensify your reaction to pollen or other substances you are allergic to</p><p>-&nbsp; psoriasis (a skin disease - scaly pink patches) or if you have ever had psoriasis</p><p>-&nbsp; if you have to have surgery, always inform your anesthetist that you are on Bivoneb before being anaesthetized.</p><p>&nbsp;</p><p>If you have serious kidney problems, do not take Bivoneb for heart failure and tell your doctor. You will be regularly monitored at the beginning of your treatment for chronic heart failure by</p><p>an experienced physician (see section 3).</p><p>This treatment should not be stopped abruptly unless clearly indicated and evaluated by your doctor (see section 3).</p><p>Children and adolescents</p><p>Because of the lack of data on the use of the product in children and adolescents, Bivoneb is <strong>not</strong></p><p>recommended for use in them.</p><p>Other medicines and Bivoneb</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Always tell your doctor if you are using or receiving any of the following medicines in addition to Bivoneb:</p><p>-&nbsp;&nbsp;&nbsp; Medicines for controlling the blood pressure or medicines for heart problems (such as amiodarone, amlodipine, cibenzoline, clonidine, digoxin, diltiazem, disopyramide, felodipine, flecainide, guanfacin, hydroquinidine, lacidipine, lidocaine, methyldopa, mexiletine, moxonidine, nicardipine, nifedipine, nimodipine, nitrendipine, propafenone, quinidine, rilmenidine, verapamil).</p><p>-&nbsp;&nbsp; Sedatives and therapies for psychosis (a mental illness) e.g. barbiturates (also used for epilepsy), phenothiazine (also used for vomiting and nausea) and thioridazine.</p><p>-&nbsp; Medicines for depression e.g. amitriptyline, paroxetine, fluoxetine.</p><p>-&nbsp; Medicines used for anaesthesia during an operation<strong><em>.</em></strong></p><p>-&nbsp; Medicines for asthma, blocked nose or certain eye disorders such as glaucoma (increased pressure in the eye) or dilation (widening) of the pupil.</p><p>-&nbsp; Baclofen (an antispasmodic drug); Amifostine (a protective medicine used during cancer treatment)</p><p>All these drugs as well as Nebivolol may influence the blood pressure and/or heart function.</p><p>-&nbsp;&nbsp; Medicines for treating excessive stomach acid or ulcers (antacid drug): you should take Bivoneb during a meal and the antacid drug between meals.</p><p>Bivoneb with food and drink</p><p>Please refer to section 3.</p><p>Pregnancy, breast feeding and fertility</p><p>Bivoneb should not be used during pregnancy, unless clearly necessary. It is not recommended for use while breast-feeding.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Driving and using machines</p><p>This medicine may cause dizziness or fatigue. If affected, <strong>do not </strong>drive or operate machinery</p><p>Bivoneb contains lactose</p><p>This product contains <strong>lactose</strong>. If you have been told by your doctor that you have an intolerance to some sugars, <strong>contact your doctor before </strong>taking this medicine.</p><p>This medicine contains less than 1mmol sodium (23 mg) per tablet, that is to say essentially</p><p>&lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bivoneb may be taken before, during or after the meal, but, alternatively, you can take it independently of meals. The tablet is best taken with some water.</p><p>Treatment of raised blood pressure (hypertension).</p><p>The usual dose is 1 tablet per day. The dose should be taken preferably at the same time of the day.</p><p>-&nbsp; Elderly patients and patients with a kidney disorder will usually start with &frac12; (half) tablet daily.</p><p>-&nbsp;&nbsp;&nbsp; The therapeutic effect on blood pressure becomes evident after 1-2 weeks of treatment. Occasionally, the optimal effect is reached only after 4 weeks.</p><p>Treatment of chronic heart failure</p><p>-&nbsp; Your treatment will be started and closely supervised by an experienced physician.</p><p>-&nbsp; Your doctor will start your treatment with &frac14; (quarter) tablet per day. This may be increased after 1-2 weeks to &frac12; (half) tablet per day, then to 1 tablet per day and then to 2 tablets per day until the correct dose is reached for you. Your doctor will prescribe the dose that is right for you at each step and you should closely follow his/her instructions.</p><p>-&nbsp; The maximum recommended dose is 2 tablets (10mg) a day.</p><p>-&nbsp; You will need to be under the close supervision for 2 hours by an experienced physician when you start treatment and every time your dose is increased</p><p>-&nbsp; Your doctor may reduce your dose if necessary</p><p>-&nbsp; You should <strong>not stop treatment abruptly </strong>as this can make your heart failure worse.</p><p>-&nbsp; Patients with serious kidney problems should not take this medicine.</p><p>-&nbsp; Take your medicine once daily, preferably at about the same time of day</p><p>If you have been told by your doctor to take &frac14; (quarter) or &frac12; (half) tablet daily, please refer to the instructions below on how to break Nebivolol Tablets 5 mg cross-scored tablets.</p><p>-&nbsp; Place the tablets onto a flat, hard surface (e.g. a table or worktop), with the cross score facing up.</p><p>-&nbsp; Break the tablet by pushing it with the index fingers of both hands placed along one break mark (Diagrams 1 and 2).</p><p>-Tablet quarters are obtained by breaking the halves in the same way (Diagrams 3 and 4).</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image1.jpeg" o:spid="_x0000_s1028" type="#_x0000_t75"
  style='position:absolute;margin-left:128.2pt;margin-top:12pt;width:293.1pt;
  height:97.25pt;z-index:251658240;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><img src="data:image/png;base64,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" alt="" width="398" height="133" vspace="0" hspace="0" border="0" style="width:398px;height:133px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Diagrams 1 and 2: Easy breaking of the Nebivolol Tablets 5 mg cross-scored tablet in half.</p><p><img src="data:image/png;base64,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" alt="" width="398" height="133" vspace="0" hspace="0" border="0" style="width:398px;height:133px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>Diagrams 3 and 4: Easy breaking of half of the Nebivolol 5 mg cross-scored tablet into quarters.</p><p>-&nbsp;&nbsp; Your doctor may decide to combine Bivoneb tablets with other medicines to treat your condition.</p><p>-&nbsp; Do not use in children or adolescents.</p><p>If you take more Bivoneb than you should</p><p>If you accidentally take an overdose of this medicine, tell your doctor of pharmacist <strong>immediately</strong>. The most frequent symptoms and signs of a Bivoneb overdose are very slow heart beat (bradycardia), low blood pressure with possible fainting (hypotension), breathlessness such as in asthma (bronchospasm), and acute heart failure.</p><p>You can take activated charcoal (which is available at your pharmacy) while you wait for the arrival of the doctor.</p><p>If you forget to take Bivoneb</p><p>If you forget a dose of Bivoneb but remember a little later on that you should have taken it, take that day&rsquo;s dose as usual. However, if a long delay has occurred (e.g. several hours), so that the next due dose is near, skip the forgotten dose and take the next, scheduled, normal dose at the usual time. Do not take a double dose. Repeated skipping, however, should be avoided.</p><p>If you stop taking Bivoneb</p><p>You should always consult with your doctor before stopping Bivoneb treatment, whether you are taking it for high blood pressure or chronic heart failure.</p><p>You should not stop Bivoneb treatment abruptly as this can temporarily make your heart failure worse. If it is necessary to stop Bivoneb treatment for chronic heart failure, the daily dose should be decreased gradually, by halving the dose, at weekly intervals.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>When <strong>Bivoneb </strong>is used for the treatment of raised blood pressure, the possible side effects are: Common side effects (may affect up to 1 in 10 people):</p><p>&nbsp;</p><p>-&nbsp; headache</p><p>-&nbsp; dizziness</p><p>-&nbsp; tiredness</p><p>-&nbsp; an unusual itching or tingling feeling</p><p>-&nbsp; diarrhoea</p><p>-&nbsp; constipation</p><p>-&nbsp; nausea</p><p>-&nbsp; shortness of breath</p><p>-&nbsp; swollen hands or feet.</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>-&nbsp; slow heartbeat or other heart complaints</p><p>-&nbsp; low blood pressure</p><p>-&nbsp; cramp-like leg pains on walking</p><p>-&nbsp; abnormal vision</p><p>-&nbsp; impotence</p><p>-&nbsp; feelings of depression</p><p>-&nbsp; digestive difficulties (dyspepsia), gas in stomach or bowel<strong><em>, </em></strong>vomiting</p><p>-&nbsp; skin rash, itchiness</p><p>-&nbsp;&nbsp; breathlessness such as in asthma, due to sudden cramps in the muscles around the airways (bronchospasm)</p><p>-&nbsp; nightmares.</p><p>Very rare side effects (may affect up to 1 in 10,000 people):</p><p>-&nbsp; fainting</p><p>-&nbsp; worsening of psoriasis (a skin disease - scaly pink patches).</p><p>&nbsp;</p><p>The following side effects have been reported only in some isolated cases during <strong>Bivoneb</strong></p><p>treatment:</p><p>-&nbsp; whole-body allergic reactions, with generalized skin eruption (hypersensitivity reactions);</p><p>-&nbsp;&nbsp; rapid-onset swelling, especially around the lips, eyes, or of the tongue with possible sudden difficulty breathing (angioedema);</p><p>-&nbsp;&nbsp; kind of skin rash notable for pale red, raised, itchy bumps of allergic or non allergic causes (urticaria).</p><p>In a clinical study for <strong>chronic heart failure, </strong>the following side effects were seen<strong>:</strong></p><p>Very common side effects (may affect more than 1 in 10 people):</p><p>-&nbsp; slow heart beat</p><p>-&nbsp; dizziness</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>-&nbsp; worsening of heart failure</p><p>-&nbsp; low blood pressure (such as feeling faint when getting up quickly)</p><p>-&nbsp; inability to tolerate this medicine</p><p>-&nbsp; a kind of light heart conduction disorder that affects heart rhythm (1st degree AV-block)</p><p>-&nbsp; swelling of the lower limbs (such as swollen ankles).</p><p>&nbsp;</p><p>Reporting of side effect</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong><em>&nbsp;&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>o Other GCC States:</em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Bivoneb (Nebivolol Tablets 5 mg) contains:</strong></p><p>The active substance is Bivoneb.</p><p>Each tablet contains Nebivolol Tablets 5 mg equivalent to 5mg of Nebivolol. The other ingredients are:</p><p>Lactose monohydrate (Pharmatose 200M), Maize starch (Extra White Maize), Croscarmellose Sodium (Ac-Di-Sol), Hypromellose, 2910 5CPS (Methocel E5 LV Premium), Polysorbate 80, (Crillet-4), Cellulose Microcrystalline (Avicel PH102), Silica Colloidal anhydrous (Aerosil 200) and Magnesium stearate (LIGAMED MF-2-V) and Purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Bivoneb (Nebivolol Tablets 5mg) looks like?



White to off-white, round biconvex tablets debossed with 'cross score line' on one side and 'H' on the other side.



How supplied:

Bivoneb (Nebivolol Tablets 5mg) are supplied in blister pack.

Bivoneb (Nebivolol Tablets 5mg) - 3X10’s Alu-Alu blister

- 6X10’s Alu-Alu blister 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer&nbsp;<br />Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 221</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August, 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بيفونب أقراص على نيبفولول هيدروكلوريد، وهو دواء للقلب والأوعية الدموية ينتمي إلى مجموعة دوائية تسمى حاصرات بيتا الانتقائية (أي يعمل انتقائي على نظام القلب والأوعية الدموية). يمنع زيادة معدل ضربات القلب، يتحكم في قوة ضخ القلب. كما أنها تساعد على تمدد الأوعية الدموية، مما يساهم أيضًا في خفض ضغط الدم.</p><p dir="RTL">يستخدم لعلاج ارتفاع ضغط الدم.</p><p dir="RTL">يستخدم بيفونب أقراص أيضًا لعلاج قصور القلب المزمن المعتدل والمتوسط لدى المرضى البالغين من العمر(70 عامًا أو أكثر)، بالإضافة إلى علاجات أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال بيفونب أقراص:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه نيبفولول أو أي من المكونات الأخرى لهذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك واحد أو أكثر من الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم منخفض</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل خطيرة في الدورة الدموية في الذراعين أو الساقين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات بطيئة للغاية (أقل من 60 نبضة في الدقيقة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المشكلات الخطيرة الأخرى المتعلقة بإيقاع القلب (مثل الإحصار الأذيني البطيني من الدرجة الثانية والثالثة، واضطرابات توصيل القلب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور القلب، الذي حدث للتو أو الذي تطور في الآونة الأخيرة إلى الأسوأ، أو أنك تتلقى علاجًا لصدمة في الدورة الدموية بسبب فشل القلب الحاد بسبب التغذية بالتنقيط عن طريق الوريد لمساعدة القلب على العمل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو أو الصفير (في الوقت الحالي أو في الماضي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم القواتم الغير المعالج، ورم يقع في أعلى الكلى (في الغدد الكظرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب وظائف الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب التمثيل الغذائي (الحماض الأيضي)، على سبيل المثال، الحماض الكيتوني السكري.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">استشر طبيبك أو الصيدلي قبل تناول بيفونب أقراص:</p><p dir="RTL">أبلغ طبيبك إذا كنت تعاني من إحدى الأعراض التالية أو تطورها:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات بطيئة بشكل غير طبيعي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من آلام الصدر بسبب التشنج القلبي الذي يحدث بشكل تلقائي والذي يسمى ذبحة برينزميتال الصدرية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل القلب المزمن غير المعالج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احصار&nbsp;القلب من الدرجة الأولى (نوع من اضطراب توصيل القلب الخفيف الذي يؤثر على إيقاع القلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الدورة الدموية في الذراعين أو الساقين، على سبيل المثال مرض أو متلازمة رينود، آلام تشبه التشنج عند المشي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التنفس لفترة طويلة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السكري: هذا الدواء ليس له أي تأثير على نسبة السكر في الدم، لكنه قد يخفي علامات التحذير من انخفاض مستوى السكر (مثل الخفقان، سرعة ضربات القلب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية: قد يخفي هذا الدواء علامات معدل ضربات القلب بسرعة غير طبيعية بسبب هذه الحالة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية: هذا الدواء قد يكثف رد فعلك على حبوب اللقاح أو غيرها من المواد التي لديك حساسية تجاهها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصدفية (مرض جلدي - بقع وردية متقشرة) أو إذا كنت قد أصبت بالصدفية من قبل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان ينبغي عليك إجراء عملية جراحية، فعليك دائمًا إخبار أخصائي التخدير أنك تتناول بيفونب أقراص قبل التخدير.</p><p dir="RTL">إذا كنت تعاني من مشاكل خطيرة في الكلى فلا تستخدم بيفونب أقراص لعلاج فشل القلب وأخبر طبيبك.</p><p dir="RTL">سيتم مراقبتك بانتظام في بداية علاجك لفشل القلب المزمن من قبل طبيب متمرس (انظر القسم 3).</p><p dir="RTL">لا ينبغي أن توقف هذا العلاج فجأة ما لم يحدد طبيبك بوضوح ويقيمه (انظر القسم 3).</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">نظرًا لنقص البيانات حول استخدام المنتج في الأطفال والمراهقين، لا ينصح باستخدام بيفونب أقراص للأطفال والمراهقين.</p><p dir="RTL"><strong>الأدوية الأخرى وبيفونب أقراص</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخرا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">أخبر طبيبك دائمًا إذا كنت تستخدم أو تتناول أيًا من الأدوية التالية بالإضافة إلى بيفونب أقراص:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية للتحكم في ضغط الدم أو أدوية لمشاكل القلب (مثل أميودارون، أملوديبين، سيبنزولين، كلونيدين، ديجوكسين، ديلتيازيم، ديسوبيراميد، فيلوديبين، فلوساينيد، جوانفاسين، هيدروكينيدين، لاكسيديبين، ليدوكايين، ميثيلوبينين، ميديوكيبين، نيموديبين، نيترينديبين، بروبافينون، كينيدين، ريلميندين، فيراباميل).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المهدئات وعلاجات الذهان (مرض عقلي) على سبيل المثال الباربيتورات (يستخدم أيضًا لعلاج الصرع)، الفينوثيازين (يستخدم أيضًا في التقيؤ والغثيان) وثيوريدازين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية للاكتئاب على سبيل المثال أميتريبتيلين، باروكستين، فلوكستين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة للتخدير أثناء العملية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية الربو والأنف المسدود أو بعض اضطرابات العين مثل الجلوكوما (زيادة الضغط في العين) أو تمدد (اتساع) بؤبؤ العين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باكلوفين (دواء مضاد للتشنج)؛ أميفوستين (دواء وقائي يستخدم خلال علاج السرطان)</p><p dir="RTL">كل هذه الأدوية وكذلك بيفونب أقراص قد تؤثر على ضغط الدم و / أو وظائف القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج الإفراط في حمض المعدة أو القرحة (دواء مضاد للحموضة): يجب أن تتناول بيفونب أقراص أثناء الوجبة والعقاقير المضادة للحموضة بين الوجبات.</p><p dir="RTL"><strong>تتناول </strong><strong>بيفونب أقراص</strong><strong> مع الطعام والشراب</strong></p><p dir="RTL">يرجى الرجوع إلى القسم 3.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">لا ينبغي استخدام بيفونب أقراص أثناء الحمل، ما لم يكن ذلك ضروريا بشكل واضح.</p><p dir="RTL">لا ينصح بالاستخدام أثناء الرضاعة الطبيعية.</p><p dir="RTL">إذا كنت حاملاً أو مرضعة، تعتقدين أنك قد تكون حاملاً أو تخططين لإنجاب طفل، اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">هذا الدواء قد يسبب الدوخة أو التعب. لا تقود أو تستخدم الآلات إذا كنت متأثرا بذلك.</p><p dir="RTL"><strong>محتوى بيفونب أقراص من اللاكتوز</strong></p><p dir="RTL">هذا المنتج يحتوي على اللاكتوز. إذا أخبر طبيبك بأنك لديك مشكلة من تحمل بعض السكريات، فاتصل بطبيبك قبل تناول هذا الدواء.</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم (23 ملغم) لكل قرص، أي &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك الطبيب. يجب عليك استشارة طبيبك إذا كنت غير متأكد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول بيفونب الأقراص قبل أو أثناء أو بعد الوجبة، ولكن بدلاً من ذلك، يمكنك تناولها بشكل مستقل عن الوجبات. من الأفضل أن تتناول قرص مع بعض الماء.</p><p dir="RTL"><strong>علاج ارتفاع ضغط الدم.</strong></p><p dir="RTL">الجرعة المعتادة هي 1 قرص يوميا. يفضل تناول الجرعة في نفس الوقت من اليوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادةً ما يبدأ المرضى المسنون والمرضى الذين يعانون من اضطرابات في الكلى بـتناول نصف قرص يوميًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يصبح التأثير العلاجي على ضغط الدم واضحا بعد 1-2 أسابيع من العلاج. في بعض الأحيان، لا يتم الوصول إلى التأثير الأمثل إلا بعد 4 أسابيع من العلاج.</p><p dir="RTL"><strong>علاج قصور القلب المزمن</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تبدأ مرحلة علاجك ويشرف عليها عن كثب طبيب متمرس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيبدأ طبيبك في علاجك باستخدام ربع قرص يوميًا. يمكن زيادته بعد أسبوع إلى أسبوعين (نصف) قرص يوميًا، ثم إلى قرص واحد يوميًا، ثم إلى قرصين يوميًا حتى الوصول إلى الجرعة الصحيحة والمناسبة لك. سيصف طبيبك الجرعة المناسبة لك في كل خطوة ويجب عليك اتباع تعليماته عن كثب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحد الأقصى من الجرعة الموصي به هو 2 قرص (10 ملغم) في اليوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تكون تحت إشراف دقيق لمدة ساعتين من قبل طبيب ذي خبرة عند بدء العلاج وفي كل مرة تزداد فيها الجرعة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لزم الأمر قد يقلل طبيبك من الجرعة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التوقف عن العلاج فجأة لأن ذلك قد يزيد من فشل القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المرضى الذين يعانون من مشاكل خطيرة في الكلى يجب عدم تناول هذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الدواء مرة واحدة يوميًا، ويفضل في نفس الوقت تقريبًا من اليوم</p><p dir="RTL">إذا أخبر طبيبك أن تتناول ربع أو نصف قرص يوميًا، فيرجى الرجوع إلى الإرشادات الواردة أدناه حول كيفية تقسيم أقراص بيفونب أقراص متعددة التقسيم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع القرص على سطح صلب مسطح (مثل طاولة أو سطح عمل)، بحيث يكون الجانب المتقاطعة متجهة لأعلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بكسر القرص عن طريق دفعه بأصابع السبابة بكلتا اليدين الموضوعة على طول علامة التقسيم (شكل 1 و2).</p><p dir="RTL">يتم الحصول على أرباع القرص عن طريق كسر النصفين بالطريقة نفسها (شكل 3 و4).</p><p dir="RTL"><img src="data:image/png;base64,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" alt="" width="398" height="133" vspace="0" hspace="0" border="0" style="width:398px;height:133px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p dir="RTL">شكل 1 و2: كسر قرص بيفونب أقراص 5 ملغم بسهولة إلى نصفين.</p><p dir="RTL"><img src="data:image/png;base64,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" alt="" width="398" height="133" vspace="0" hspace="0" border="0" style="width:398px;height:133px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p dir="RTL">شكل 3 و4: كسر نصف قرص بيفونب أقراص 5 ملغم بسهولة إلى ربعين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقرر طبيبك دمج تناول بيفونب أقراص مع أدوية أخرى لعلاج حالتك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم في حالة الأطفال أو المراهقين.</p><p dir="RTL"><strong>تناول جرعة زائدة من أقراص بيفونب أقراص</strong></p><p dir="RTL">إذا تناولت جرعة زائدة من هذا الدواء عن طريق الخطأ، أخبر طبيبك على الفور. من أعراض الجرعة الزائدة لبيفونب أقراص هي بطء شديد في ضربات القلب، انخفاض ضغط الدم مع احتمالية الإغماء، ضيق التنفس كما هو الحال في الربو (تشنج قصبي)، وفشل القلب الحاد.</p><p dir="RTL">يمكنك أن تتناول الفحم النشط (والذي يتوفر في الصيدلية) أثناء انتظار وصول الطبيب.</p><p dir="RTL"><strong>نسيان تناول أقراص من بيفونب أقراص</strong></p><p dir="RTL">إذا نسيت تناول جرعة بيفونب أقراص، تناولها حينما تتذكرها ومع ذلك. إذا حدث تأخير لفترة طويلة (على سبيل المثال عدة ساعات)، بحيث اقترب موعد الجرعة التالية المستحقة، فيجب تخطي الجرعة المنسية وتناول الجرعة التالية المعتادة في الوقت المعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>التوقف عن تناول بيفونب أقراص</strong></p><p dir="RTL">يجب عليك دائمًا استشارة طبيبك قبل إيقاف العلاج باستخدام بيفونب أقراص، سواء كنت تتناوله لارتفاع ضغط الدم أو قصور القلب المزمن.</p><p dir="RTL">يجب عدم التوقف عن العلاج باستخدام بيفونب أقراص فجأة لأن هذا يمكن أن يؤدي إلى فشل القلب بشكل مؤقت. إذا كان من الضروري إيقاف العلاج باستخدام بيفونب أقراص لفشل القلب المزمن، فينبغي تخفيض الجرعة اليومية تدريجياً، عن طريق خفض الجرعة إلى النصف، على فترات أسبوعية.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL">عند استخدام بيفونب أقراص في علاج ارتفاع ضغط الدم، فإن الآثار الجانبية المحتملة هي:</p><p dir="RTL">الآثار الجانبية الشائعة (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع بالرأس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة غير عادية أو شعور بالوخز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين أو القدمين.</p><p dir="RTL">الآثار الجانبية غير الشائعة (قد تؤثر على ما يصل إلى 1 من كل 100 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات بطيئة أو شكاوى قلبية أخرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم منخفض</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام بالساق تشبه التشنج مع المشي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية غير طبيعية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف جنسي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالاكتئاب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم، غازات في المعدة أو الأمعاء، قيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس كما هو الحال في الربو، بسبب التشنجات المفاجئة في العضلات حول الشعب الهوائية (تشنج قصبي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوابيس.</p><p dir="RTL">الآثار الجانبية النادرة (قد تؤثر على ما يصل إلى 1 من كل 10000 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم الصدفية (مرض جلدي - بقع وردية متقشرة).</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية فقط في بعض الحالات الفردية أثناء العلاج بتناول بيفونب أقراص:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تفاعلات حساسية بالجسم كاملا، مع طفح جلدي عام (تفاعلات فرط الحساسية)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم سريع الظهور، خاصة حول الشفاه أو العينين أو اللسان مع وجود صعوبة مفاجئة في التنفس (وذمة وعائية)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من الطفح الجلدي المشهور بسبب النتوءات الحمراء المرتفعة والمحفوفة بحساسية أو غير مسببة للحساسية (الشرى).</p><p dir="RTL">في دراسة سريرية لفشل القلب المزمن، شوهدت الآثار الجانبية التالية:</p><p dir="RTL">آثار جانبية شائعة جدًا (قد تؤثر على أكثر من شخص من كل 10 أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات بطيئة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">الآثار الجانبية الشائعة (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم قصور القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (مثل الشعور بالإغماء عند النهوض بسرعة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على تحمل هذا الدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من اضطراب توصيل القلب الخفيف الذي يؤثر على إيقاع القلب (الإحصار الأذيني البطيني من الدرجة الأولى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الأطراف السفلية (مثل تورم الكاحلين).</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='font-size:9.0pt;line-height:115%;font-family:"Arial",sans-serif'><span
  style='mso-element:field-begin;mso-field-lock:yes'></span></span><span
  dir=LTR></span><span dir=LTR></span><span dir=LTR style='font-size:9.0pt;
  line-height:115%;font-family:"Arial",sans-serif'><span dir=LTR></span><span
  dir=LTR></span><span style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222&nbsp;&nbsp; ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR style='font-size:9.0pt;line-height:115%;font-family:"Arial",sans-serif'><v:shape
   id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في عبوته الأصلية للحماية من الرطوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم بيفونب أقراص بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ما يحتوي عليه بيفونب أقراص 5 ملغم:</p><p dir="RTL">المادة الفعالة هي نيبفولول هيدروكلوريد.</p><p dir="RTL">يحتوي كل قرص على ما يعادل 5 ملغم من نيبفولول.</p><p dir="RTL">.</p><p dir="RTL"><strong>الصواغات الأخرى هي</strong>: السليلوز دقيق التبلور، اللاكتوز أحادي الهيدرات، نشا الذرة، كروسكارميلوز الصوديوم، هيبروميلوز 2910 5 CPS المتوافق مع دستور الأدوية الأوروبي، بولي سوربات 80، السيليكا الغروية اللامائية، ماء نقي، ستيرات الماغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل بيفونب أقراص 5 ملغم ومحتويات العلبة؟</strong></p><p dir="RTL">أقراص دائرية الشكل ذات لون الأبيض القاتم إلى الأبيض محدبة الوجهين ومدموغة بحرف &quot;H&quot; من جانب وخطوط تقسيم على الجانب الآخر.</p><p dir="RTL"><strong>توافر بيفونب أقراص:</strong></p><p dir="RTL">يتوافر بيفونب أقراص 5 ملغم في عبوات حاوية.</p><p dir="RTL">تحتوي عبوة بيفونب أقراص 5 ملغم على 30 قرص أو 60 قرص عبارة عن ثلاثة أو ستة شرائط (Alu-Alu) بكل منها 10 أقراص</p><p dir="RTL">قد لا تتوافر كافة العبوات في السوق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p dir="RTL">المملكة العربية السعودية.</p><p dir="RTL">تليفون: + 966 114772215</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             نوفمبر 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bivoneb (Nebivolol Tablets 5mg) 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains Nebivolol Hydrochloride equivalent to 5 mg of Nebivolol 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to off-white, round biconvex tablets debossed with 'cross score line' on one side and 'H' on the other side. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypertension&nbsp;</p><p>Treatment of essential hypertension.</p><p>Chronic heart failure (CHF)&nbsp;</p><p>Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients &ge; 70 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u>&nbsp;</p><p>Hypertension&nbsp;</p><p>Adults&nbsp;</p><p>The dose is one tablet (5 mg) daily, preferably at the same time of the day.&nbsp;</p><p>The blood pressure lowering effect becomes evident after 1-2 weeks of treatment. Occasionally, the optimal effect is reached only after 4 weeks.</p><p>Combination with other antihypertensive agents &nbsp;</p><p>Beta-blockers can be used alone or concomitantly with other antihypertensive agents. To date, an additional antihypertensive effect has been observed only when Nebivolol Hydrochlorides combined with hydrochlorothiazide 12.5-25 mg.</p><p>Patients with renal insufficiency&nbsp;</p><p>In patients with renal insufficiency, the recommended starting dose is 2.5 mg daily. If needed, the daily dose may be increased to 5 mg.</p><p>Patients with hepatic insufficiency&nbsp;</p><p>Data in patients with hepatic insufficiency or impaired liver function are limited. Therefore the use of Nebivolol Hydrochloride in these patients is contra-indicated.</p><p>Older people&nbsp;</p><p>In patients over 65 years, the recommended starting dose is 2.5 mg daily. If needed, the daily dose may be increased to 5 mg. However, in view of the limited experience in patients above 75 years, caution must be exercised and these patients monitored closely.</p><p>Paediatric population&nbsp;</p><p>The efficacy and safety of Nebivolol Hydrochloride in children and adolescents aged below 18 years has not been established. No data are available. Therefore, use in children and adolescents is not recommended.</p><p>Chronic heart failure (CHF)&nbsp;</p><p>The treatment of stable chronic heart failure has to be initiated with a gradual up titration of dosage until the optimal individual maintenance dose is reached.&nbsp;</p><p>Patients should have stable chronic heart failure without acute failure during the past six weeks. It is recommended that the treating physician should be experienced in the management of chronic heart failure.</p><p>For those patients receiving cardiovascular drug therapy including diuretics and/or digoxin and/or ACE inhibitors and/or angiotensin II antagonists, dosing of these drugs should be stabilised during the past two weeks prior to initiation of Nebivolol Hydrochloride treatment.</p><p>The initial up titration should be done according to the following steps at 1-2 weekly intervals based on patient tolerability:</p><p>1.25 mg Nebivolol, to be increased to 2.5 mg Nebivolol once daily, then to 5 mg once daily and then to 10 mg once daily.</p><p>The maximum recommended dose is 10 mg Nebivolol once daily.</p><p>Initiation of therapy and every dose increase should be done under the supervision of an experienced physician over a period of at least 2 hours to ensure that the clinical status (especially as regards blood pressure, heart rate, conduction disturbances, signs of worsening of heart failure) remains stable.</p><p>Occurrence of adverse events may prevent all patients being treated with the maximum recommended dose. If necessary, the dose reached can also be decreased step by step and reintroduced as appropriate.</p><p>During the titration phase, in case of worsening of the heart failure or intolerance, it is recommended first to reduce the dose of Nebivolol, or to stop it immediately if necessary (in case of severe hypotension, worsening of heart failure with acute pulmonary oedema, cardiogenic shock, symptomatic bradycardia or AV block).</p><p>Treatment of stable chronic heart failure with Nebivolol is generally a long-term treatment.</p><p>The treatment with Nebivolol is not recommended to be stopped abruptly since this might lead to a transitory worsening of heart failure. If discontinuation is necessary, the dose should be gradually decreased divided into halves weekly.</p><p>Patients with renal insufficiency&nbsp;</p><p>No dose adjustment is required in mild to moderate renal insufficiency since up titration to the maximum tolerated dose is individually adjusted. There is no experience in patients with severe renal insufficiency (serum creatinine &ge; 250&mu;mol/L). Therefore, the use of Nebivolol in these patients is not recommended.</p><p>Patients with hepatic insufficiency&nbsp;</p><p>Data in patients with hepatic insufficiency are limited. Therefore the use of Nebivolol Hydrochloride in these patients is contra-indicated.</p><p>Older people&nbsp;</p><p>No dose adjustment is required since up titration to the maximum tolerated dose is individually adjusted.&nbsp;</p><p>Paediatric population&nbsp;</p><p>The efficacy and safety of Nebivolol Hydrochloride in children and adolescents aged below 18 years has not been established. Therefore, use in children and adolescents is not recommended.</p><p>No data are available. Method of administration&nbsp;</p><p>Oral use.</p><p>Tablets may be taken with meals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
-	Liver insufficiency or liver function impairment. 
-	Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring i.v. 
inotropic therapy. 
In addition, as with other beta-blocking agents, Nebivolol Hydrochloride is contra-indicated in: 
•	sick sinus syndrome, including sino-atrial block. 
•	second and third degree heart block (without a pacemaker). 
•	history of bronchospasm and bronchial asthma. 
•	untreated phaeochromocytoma. 
•	metabolic acidosis.  
•	bradycardia (heart rate < 60 bpm prior to start therapy).  
•	hypotension (systolic blood pressure < 90 mmHg).  
•	severe peripheral circulatory disturbances 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following warnings and precautions apply to beta-adrenergic antagonists in general.</p><p>Anesthesia&nbsp;</p><p>Continuation of beta-blockade reduces the risk of arrhythmias during induction and intubation. If beta-blockade is interrupted in preparation for surgery, the beta-adrenergic antagonist should be discontinued at least 24 hours beforehand.&nbsp;</p><p>Caution should be observed with certain anesthetics that cause myocardial depression. The patient can be protected against vagal reactions by intravenous administration of atropine.</p><p>Cardiovascular&nbsp;</p><p>In general, beta-adrenergic antagonists should not be used in patients with untreated congestive heart failure (CHF), unless their condition has been stabilised.</p><p>In patients with ischaemic heart disease, treatment with a beta-adrenergic antagonist should be discontinued gradually, i.e. over 1-2 weeks. If necessary replacement therapy should be initiated at the same time, to prevent exacerbation of angina pectoris.</p><p>Beta-adrenergic antagonists may induce bradycardia: if the pulse rate drops below 50-55 bpm at rest and/or the patient experiences symptoms that are suggestive of bradycardia, the dosage should be reduced.&nbsp;</p><p>Beta-adrenergic antagonists should be used with caution:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with peripheral circulatory disorders (Raynaud&#39;s disease or syndrome, intermittent claudication), as aggravation of these disorders may occur;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with first degree heart block, because of the negative effect of beta-blockers on conduction time;&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with Prinzmetal&#39;s angina due to unopposed alpha receptor mediated coronary artery vasoconstriction: beta-adrenergic antagonists may increase the number and duration of anginal attacks.</p><p>Combination of Nebivolol with calcium channel antagonists of the verapamil and diltiazem type, with Class I antiarrhythmic drugs, and with centrally acting antihypertensive drugs is generally not recommended, for details please refer to section 4.5.</p><p>Metabolic/Endocrinological&nbsp;</p><p>Nebivolol Hydrochloride does not affect glucose levels in diabetic patients. Care should be taken in diabetic patients however, as Nebivolol may mask certain symptoms of hypoglycemia (tachycardia, palpitations).</p><p>Beta-adrenergic blocking agents may mask tachycardic symptoms in hyperthyroidism. Abrupt withdrawal may intensify symptoms.</p><p>Respiratory&nbsp;</p><p>In patients with chronic obstructive pulmonary disorders, beta-adrenergic antagonists should be used with caution as airway constriction may be aggravated.</p><p>Other&nbsp;</p><p>Patients with a history of psoriasis should take beta-adrenergic antagonists only after careful consideration.</p><p>Beta-adrenergic antagonists may increase the sensitivity to allergens and the severity of anaphylactic reactions.</p><p>The initiation of Chronic Heart Failure treatment with Nebivolol necessitates regular monitoring. For the posology and method of administration please refer to section 4.2. Treatment discontinuation should not be done abruptly unless clearly indicated. For further information please refer to section 4.2.</p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic interactions:</u>&nbsp;</p><p>The following interactions apply to beta-adrenergic antagonists in general.</p><p><u>Combinations not recommended:</u>&nbsp;</p><p><em>Class I antiarrhythmics (quinidine, hydroquinidine, cibenzoline, flecainide, disopyramide, lidocaine, mexiletine, propafenone): </em>effect on atrio-ventricular conduction time may be potentiated and negative inotropic effect increased (see section 4.4).</p><p><em>Calcium channel antagonists of verapamil/diltiazem type: </em>negative influence on contractility and atrio-ventricular conduction. Intravenous administration of verapamil in patients with &szlig;-blocker treatment may lead to profound hypotension and atrio-ventricular block (see section 4.4).</p><p><em>Centrally-acting antihypertensives (clonidine, guanfacin, moxonidine, methyldopa, rilmenidine): </em>concomitant use of centrally acting antihypertensive drugs may worsen heart failure by a decrease in the central sympathetic tonus (reduction of heart rate and cardiac output, vasodilation) (see section 4.4). Abrupt withdrawal, particularly if prior to beta-blocker discontinuation, may increase risk of &ldquo;rebound hypertension&rdquo;.</p><p>Combinations to be used with caution&nbsp;</p><p><em>Class III antiarrhythmic drugs (Amiodarone): </em>effect on atrio-ventricular conduction time may be potentiated.</p><p><em>Anaesthetics - volatile halogenated:</em> concomitant use of beta-adrenergic antagonists and anaesthetics may attenuate reflex tachycardia and increase the risk of hypotension (see section 4.4). As a general rule, avoid sudden withdrawal of beta-blocker treatment. The anaesthesiologist should be informed when the patient is receiving Nebivolol Hydrochloride.</p><p><em>Insulin and oral antidiabetic drugs: </em>although Nebivolol does not affect glucose level, concomitant use may mask certain symptoms of hypoglycaemia (palpitations, tachycardia).</p><p><em>Baclofen (antispastic agent), amifostine (antineoplastic adjunct): </em>concomitant use with antihypertensives is likely to increase the fall in blood pressure, therefore the dosage of the antihypertensive medication should be adjusted accordingly.</p><p>Combinations to be considered&nbsp;</p><p><em>Digitalis glycosides: </em>concomitant use may increase atrio-ventricular conduction time. Clinical trials with Nebivolol have not shown any clinical evidence of an interaction. Nebivolol does not influence the kinetics of digoxin.</p><p><em>Calcium antagonists of the dihydropyridine type (amlodipine, felodipine, lacidipine, nifedipine, nicardipine, nimodipine, nitrendipine): </em>concomitant use may increase the risk of hypotension, and an increase in the risk of a further deterioration of the ventricular pump function in patients with heart failure cannot be excluded.</p><p><em>Antipsychotics, antidepressants (tricyclics, barbiturates and phenothiazines): </em>concomitant use may enhance the hypothensive effect of the beta-blockers (additive effect).</p><p><em>Non steroidal anti-inflammatory drugs (NSAID): </em>no effect on the blood pressure lowering effect of nebivolol.</p><p><em>Sympathicomimetic agents: </em>concomitant use may counteract the effect of beta-adrenergic antagonists. Beta-adrenergic agents may lead to unopposed alpha-adrenergic activity of sympathicomimetic agents with both alpha- and beta-adrenergic effects (risk of hypertension, severe bradycardia and heart block).</p><p><u>Pharmacokinetic interactions:</u>&nbsp;</p><p>As Nebivolol metabolism involves the CYP2D6 isoenzyme, co-administration with substances inhibiting this enzyme, especially paroxetine, fluoxetine, thioridazine and quinidine may lead to increased plasma levels of Nebivolol associated with an increased risk of excessive bradycardia and adverse events.&nbsp;</p><p>Co-administration of cimetidine increased the plasma levels of Nebivolol, without changing the clinical effect. Co-administration of ranitidine did not affect the pharmacokinetics of Nebivolol. Provided Nebivolol Hydrochloride is taken with the meal, and an antacid between meals, the two treatments can be co-prescribed.&nbsp;</p><p>Combining Nebivolol with nicardipine slightly increased the plasma levels of both drugs, without changing the clinical effect. Co-administration of alcohol, furosemide or hydrochlorothiazide did not affect the pharmacokinetics of Nebivolol. Nebivolol does not affect the pharmacokinetics and pharmacodynamics of warfarin.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy&nbsp;</u></p><p>Nebivolol has pharmacological effects that may cause harmful effects on pregnancy and/or the foetus/newborn. In general, beta-adrenoceptor blockers reduce placental perfusion, which has been associated with growth retardation, intrauterine death, abortion or early labour. Adverse effects (e.g. hypoglycaemia and bradycardia) may occur in the foetus and newborn infant. If treatment with beta-adrenoceptor blockers is necessary, beta<sub>1</sub>-selective adrenoceptor blockers are preferable.</p><p>Nebivolol should not be used during pregnancy unless clearly necessary. If treatment with Nebivolol is considered necessary, the uteroplacental blood flow and the foetal growth should be monitored. In case of harmful effects on pregnancy or the foetus alternative treatment should be considered. The newborn infant must be closely monitored. Symptoms of hypoglycaemia and bradycardia are generally to be expected within the first 3 days.</p><p><u>Breast-feeding&nbsp;</u></p><p>Animal studies have shown that Nebivolol is excreted in breast milk. It is not known whether this drug is excreted in human milk. Most beta-blockers, particularly lipophilic compounds like Nebivolol and its active metabolites, pass into breast milk although to a variable extent.</p><p>Therefore, breastfeeding is not recommended during administration of Nebivolol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Pharmacodynamic studies have shown that Nebivolol Hydrochloride does not affect psychomotor function. When driving vehicles or operating machines it should be taken into account that dizziness and fatigue may occasionally occur</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse events are listed separately for hypertension and CHF because of differences in the background diseases.</p><p>Hypertension&nbsp;</p><p>The adverse reactions reported, which are in most of the cases of mild to moderate intensity, are tabulated below, classified by system organ class and ordered by frequency:&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>SYSTEM ORGAN</p><p>CLASS</p></td><td style="vertical-align:top"><p>Common</p><p>(&ge;1/100 to &lt; 1/10)</p></td><td style="vertical-align:top"><p>Uncommon</p><p>(&ge;1/1,000 to &le;1/100)</p></td><td style="vertical-align:top"><p>Very Rare (&le;1/10,000)</p></td><td><p>Not Known</p></td></tr><tr><td><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>angioneurotic oedema,</p><p>hypersensitivity</p></td></tr><tr><td><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>nightmares;</p><p>depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>headache, dizziness, paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>syncope</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>impaired vision</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>bradycardia, heart</p><p>failure, slowed AV</p><p>conduction/AVblock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypotension,</p><p>(increase of) intermittent</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>claudication</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>dyspnoea</p></td><td><p>bronchospasm</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>constipation, nausea, diarrhoea</p></td><td style="vertical-align:top"><p>dyspepsia, flatulence, vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>pruritus, rash erythematous</p></td><td><p>psoriasis aggravated</p></td><td><p>urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>impotence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td><p>tiredness, oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>The following adverse reactions have also been reported with some beta adrenergic antagonists: hallucinations, psychoses, confusion, cold/cyanotic extremities, Raynaud phenomenon, dry eyes, and oculo-mucocutaneous toxicity of the practolol-type.</p><p>Chronic heart failure&nbsp;</p><p>Data on adverse reactions in CHF patients are available from one placebo-controlled clinical trial involving 1067 patients taking Nebivolol and 1061 patients taking placebo. In this study, a total of 449 Nebivolol patients (42.1%) reported at least possibly causally related adverse reactions compared to 334 placebo patients (31.5%). The most commonly reported adverse reactions in Nebivolol patients were bradycardia and dizziness, both occurring in approximately 11% of patients. The corresponding frequencies among placebo patients were approximately 2% and 7%, respectively.&nbsp;</p><p>The following incidences were reported for adverse reactions (at least possibly drug-related) which are considered specifically relevant in the treatment of chronic heart failure:&nbsp;</p><p>-&nbsp;&nbsp; Aggravation of cardiac failure occurred in 5.8 % of Nebivolol patients compared to 5.2% of placebo patients.</p><p>-&nbsp;&nbsp; Postural hypotension was reported in 2.1% of Nebivolol patients compared to 1.0% of placebo patients.&nbsp;</p><p>-&nbsp;&nbsp; Drug intolerance occurred in 1.6% of Nebivolol patients compared to 0.8% of placebo patients.&nbsp;</p><p>-&nbsp;&nbsp; First degree atrio-ventricular block occurred in 1.4% of Nebivolol patients compared to 0.9% of placebo patients.</p><p>-&nbsp;&nbsp; Oedema of the lower limb were reported by 1.0% of Nebivolol patients compared to 0.2% of placebo patients</p><p><u><strong>Reporting of suspected adverse reactions&nbsp;</strong></u></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia<em>: </em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:510px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>o Other GCC States: </strong></p><p>&nbsp;Please contact the relevant competent authority.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available on over dosage with Nebivolol Hydrochloride.</p><p>Symptoms&nbsp;</p><p>Symptoms of over dosage with beta-blockers are: bradycardia, hypotension, bronchospasm and acute cardiac insufficiency.</p><p>Treatment&nbsp;</p><p>In case of over dosage or hypersensitivity, the patient should be kept under close supervision and be treated in an intensive care ward. Blood glucose levels should be checked. Absorption of any drug residues still present in the gastro-intestinal tract can be prevented by gastric lavage and the administration of activated charcoal and a laxative. Artificial respiration may be required. Bradycardia or extensive vagal reactions should be treated by administering atropine or methyl atropine. Hypotension and shock should be treated with plasma/plasma substitutes and, if necessary, catecholamines. The beta-blocking effect can be counteracted by slow intravenous administration of isoprenaline hydrochloride, starting with a dose of approximately 5 &mu;g/minute, or dobutamine, starting with a dose of 2.5 &mu;g/minute, until the required effect has been obtained. In refractory cases isoprenaline can be combined with dopamine. If this does not produce the desired effect either, intravenous administration of glucagon 50-100 &mu;g/kg i.v. may be considered. If required, the injection should be repeated within one hour, to be followed -if required- by an i.v. infusion of glucagon 70 &mu;g/kg/h. In extreme cases of treatment-resistant bradycardia, a pacemaker may be inserted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Beta blocking agent, selective.&nbsp;</p><p>ATC code: C07AB12</p><p>Nebivolol is a racemate of two enantiomers, SRRR-Nebivolol (or d-Nebivolol) and RSSSNebivolol (or l-Nebivolol). It combines two pharmacological activities:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is a competitive and selective beta-receptor antagonist: this effect is attributed to the SRRRenantiomer (d-enantiomer).&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It has mild vasodilating properties due to an interaction with the L-arginine/nitric oxide pathway.&nbsp;</p><p>Single and repeated doses of Nebivolol reduce heart rate and blood pressure at rest and during exercise, both in normotensive subjects and in hypertensive patients. The antihypertensive effect is maintained during chronic treatment.</p><p>At therapeutic doses, Nebivolol is devoid of alpha-adrenergic antagonism.&nbsp;</p><p>During acute and chronic treatment with Nebivolol in hypertensive patients systemic vascular resistance is decreased. Despite heart rate reduction, reduction in cardiac output during rest and exercise may be limited due to an increase in stroke volume. The clinical relevance of these hemodynamic differences as compared to other beta1 receptor antagonists has not been fully established.</p><p>In hypertensive patients, Nebivolol increases the NO-mediated vascular response to acetylcholine (ACh) which is reduced in patients with endothelial dysfunction.</p><p>In a mortality&ndash;morbidity, placebo-controlled trial performed in 2128 patients &ge; 70 years (median age 75.2 years) with stable chronic heart failure with or without impaired left ventricular ejection fraction (mean LVEF: 36 &plusmn; 12.3%, with the following distribution: LVEF less than 35% in 56% of patients, LVEF between 35% and 45% in 25% of patients and LVEF greater than 45% in 19% of patients) followed for a mean time of 20 months, Nebivolol, on top of standard therapy, significantly prolonged the time to occurrence of deaths or hospitalisations for cardiovascular reasons (primary end-point for efficacy) with a relative risk reduction of 14% (absolute reduction: 4.2%). This risk reduction developed after 6 months of treatment and was maintained for all treatment duration (median duration: 18 months). The effect of Nebivolol was independent from age, gender, or left ventricular ejection fraction of the population on study. The benefit on all cause mortality did not reach statistical significance in comparison to placebo (absolute reduction: 2.3%).&nbsp;</p><p>A decrease in sudden death was observed in Nebivolol treated patients (4.1% vs 6.6%, relative reduction of 38%).&nbsp;</p><p>In vitro and in vivo experiments in animals showed that Nebivolol has no intrinsic sympathomimetic activity.&nbsp;</p><p>In vitro and in vivo experiments in animals showed that at pharmacological doses Nebivolol has no membrane stabilizing action.&nbsp;</p><p>In healthy volunteers, Nebivolol has no significant effect on maximal exercise capacity or endurance.&nbsp;</p><p>Available preclinical and clinical evidence in hypertensive patients has not shown that Nebivolol has a detrimental effect on erectile function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Both Nebivolol enantiomers are rapidly absorbed after oral administration. The absorption of Nebivolol is not affected by food; Nebivolol can be given with or without meals.&nbsp;</p><p>Nebivolol is extensively metabolised, partly to active hydroxy-metabolites. Nebivolol is metabolised via alicyclic and aromatic hydroxylation, N-dealkylation and glucuronidation; in addition, glucuronides of the hydroxy-metabolites are formed. The metabolism of Nebivolol by aromatic hydroxylation is subject to the CYP2D6 dependent genetic oxidative polymorphism. The oral bioavailability of Nebivolol averages 12% in fast metabolisers and is virtually complete in slow metabolisers. At steady state and at the same dose level, the peak plasma concentration of unchanged Nebivolol is about 23 times higher in poor metabolisers than in extensive metabolisers. When unchanged drug plus active metabolites are considered, the difference in peak plasma concentrations is 1.3 to 1.4 fold. Because of the variation in rates of metabolism, the dose of Nebivolol Hydrochloride should always be adjusted to the individual requirements of the patient: poor metabolisers therefore may require lower doses.</p><p>In fast metabolisers, elimination half-lives of the Nebivolol enantiomers average 10 hours. In slow metabolisers, they are 3-5 times longer. In fast metabolisers, plasma levels of the RSSSenantiomer are slightly higher than for the SRRR-enantiomer. In slow metabolisers, this difference is larger. In fast metabolisers, elimination half-lives of the hydroxymetabolites of both enantiomers average 24 hours, and are about twice as long in slow metabolisers.</p><p>Steady-state plasma levels in most subjects (fast metabolisers) are reached within 24 hours for Nebivolol and within a few days for the hydroxy-metabolites.</p><p>Plasma concentrations are dose-proportional between 1 and 30 mg. The pharmacokinetics of Nebivolol are not affected by age.</p><p>In plasma, both Nebivolol enantiomers are predominantly bound to albumin.</p><p>Plasma protein binding is 98.1% for SRRR-Nebivolol and 97.9% for RSSS-Nebivolol.</p><p>One week after administration, 38% of the dose is excreted in the urine and 48% in the faeces.</p><p>Urinary excretion of unchanged Nebivolol is less than 0.5% of the dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of genotoxicity and carcinogenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate (Pharmatose 200M), Maize starch (Extra White Maize), Croscarmellose Sodium (Ac-Di-Sol), Hypromellose, 2910 5CPS (Methocel E5 LV Premium), Polysorbate 80, (Crillet-4), Cellulose Microcrystalline (Avicel PH102), Silica Colloidal anhydrous (Aerosil 200) and Magnesium stearate (LIGAMED MF-2-V) and Purified water.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6 X 10&rsquo;s Alu-Alu Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company 
Aljameah Street, Malaz quarter,  
Riyadh 11441, Saudi Arabia 
Tel: +966 11 477 2215 
Manufacture: 
Hetero Lab Limited Unit III, Hyderabad, India. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>